WARF Signs License Agreement with Pfizer for Human Embryonic Stem Cells
News May 15, 2009
Pfizer, Inc and the Wisconsin Alumni Research Foundation (WARF) announced that they have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies.
The WARF license provides Pfizer the rights to work with hES cells for drug research and discovery. Securing appropriate licenses, in an area as broad moving as regenerative medicine, helps ensure efficient utilization of the many existing discoveries and inventions in this field and allows for the efficient transfer of information for development of future inventions.
"Our license with WARF provides us with information and materials that will allow us to use their cell lines to explore a whole new range of therapies," said Ruth McKernan, PhD, chief scientific officer of Pfizer Regenerative Medicine. "Stem cells can be used to create specialized human tissue. Our scientists will determine how new medicines may be able to improve the way stem cells regenerate damaged tissues. We will be optimizing the production of cells that could, one day, be used for therapeutic purposes."
"Pfizer's stem-cell R&D goal is three fold: to use human cells as tools in our drug discovery efforts, to improve the safety of new treatments and, most importantly, to move towards cell therapy," said McKernan. "The benefit to public health could be tremendous as we pursue our discoveries to advance the treatment of debilitating diseases."
"We are pleased to enter into this licensing agreement with Pfizer," said Carl E. Gulbrandsen, managing director of WARF. "Pfizer's access to this key intellectual property may have far-reaching benefits for both public health and Wisconsin's growing biotechnology industry."
As advances in health care help people live longer, the need for new medicines to keep people healthy continues to grow. Pfizer researchers and scientists are working to discover and develop new ways to treat and prevent life-threatening and debilitating illnesses, as well as to improve wellness and quality of life.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Stem Cell Signaling Drives Mammary Gland DevelopmentNews
New research illuminates the biology of breast tissue development and may pave the way to new strategies for diagnosing or even treating cancer.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018
Epigenetics in the nervous system: development and disease
Oct 01 - Oct 03, 2018